Clinical Trial

Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy

Name: Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy — clinical trial record (NCT07461441)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: HANGANG

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

To evaluate the Efficacy of a personalized treat-and-extend regimen of faricimab for treatment-naive polypoidal choroidal vasculopathy

Trial Details

NCT Number	NCT07461441
Lead Sponsor	Yeungnam University College of Medicine
Conditions	Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration
Enrollment	50 participants
Start Date	2026-03-01
Primary Completion	2028-11-30 (estimated)
Study Completion	2028-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-10